Article

AEYE Health reports results of its AI algorithm for autonomous screening and detection of diabetic retinopathy

The company noted that the study was the first to evaluate whether AI software can accurately detect more-than-mild diabetic retinopathy using a single image per eye, obtained from either a desktop or handheld retinal camera.

AEYE Health is reporting results from its pivotal FDA-clinical trial for the autonomous detection of more-than-mild diabetic retinopathy.

According to the company, the study was the first of its kind to evaluate whether AI software can accurately detect more-than-mild diabetic retinopathy using a single image per eye, obtained from either a desktop or handheld retinal camera.

Using a single image from each eye can simplify the diagnostic procedure and reduce screening time.

The observed AI results for each camera system:

  • Topcon NW-400 (desktop camera): 93.0% sensitivity, 91.4% specificity, >99% imageability
  • Optomed Aurora (handheld camera): 91.9% sensitivity, 93.6% specificity, >99% imageability

A single image per eye was used for both the desktop and the handheld cameras.

There are 35 million diabetics in the United States and more than 420 million worldwide who are at risk of developing diabetic retinopathy requiring an annual screening. Early diagnosis and intervention are key for sight-loss prevention. More than a third of diabetics over the age of 40 will develop diabetic retinopathy, however only 15% to 50% of patients undergo screening.

Autonomous screening in primary care setting requiring only a single image per eye obtained from a cost-effective handheld camera can improve adherence to screening protocols and ultimately prevent blindness in diabetics at risk for vision loss.

AEYE Health is seeking FDA clearance for its autonomous screening solution for diabetic retinopathy.

In addition, the company is preparing to publish its results in diagnosing glaucoma using digital fundus images.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
© 2025 MJH Life Sciences

All rights reserved.